BR0309965A - ácidos carboxìlicos com quinolona substituìda, seus derivados, local de ação, e usos dos mesmos - Google Patents

ácidos carboxìlicos com quinolona substituìda, seus derivados, local de ação, e usos dos mesmos

Info

Publication number
BR0309965A
BR0309965A BR0309965-2A BR0309965A BR0309965A BR 0309965 A BR0309965 A BR 0309965A BR 0309965 A BR0309965 A BR 0309965A BR 0309965 A BR0309965 A BR 0309965A
Authority
BR
Brazil
Prior art keywords
derivatives
carboxylic acids
gaba
action
site
Prior art date
Application number
BR0309965-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Timothy B C Johnstone
Derk J Hogenkamp
Kelvin W Gee
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR0309965A publication Critical patent/BR0309965A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR0309965-2A 2002-05-14 2003-05-12 ácidos carboxìlicos com quinolona substituìda, seus derivados, local de ação, e usos dos mesmos BR0309965A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38064102P 2002-05-14 2002-05-14
PCT/US2003/014948 WO2003097564A2 (en) 2002-05-14 2003-05-12 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Publications (1)

Publication Number Publication Date
BR0309965A true BR0309965A (pt) 2005-03-01

Family

ID=29549994

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309965-2A BR0309965A (pt) 2002-05-14 2003-05-12 ácidos carboxìlicos com quinolona substituìda, seus derivados, local de ação, e usos dos mesmos

Country Status (16)

Country Link
US (2) US7355047B2 (enExample)
EP (1) EP1503759B1 (enExample)
JP (1) JP4532263B2 (enExample)
KR (1) KR20040107525A (enExample)
CN (1) CN1652784A (enExample)
AT (1) ATE417613T1 (enExample)
AU (1) AU2003229043B2 (enExample)
BR (1) BR0309965A (enExample)
CA (1) CA2484308A1 (enExample)
DE (1) DE60325347D1 (enExample)
DK (1) DK1503759T3 (enExample)
ES (1) ES2319176T3 (enExample)
IL (1) IL164734A0 (enExample)
MX (1) MXPA04011156A (enExample)
NZ (1) NZ536061A (enExample)
WO (1) WO2003097564A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1503759B1 (en) * 2002-05-14 2008-12-17 The Regents Of The University Of California Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7825278B2 (en) * 2004-05-06 2010-11-02 The Regents Of The University Of California Substituted enaminones, their derivatives and uses thereof
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
JP4796622B2 (ja) * 2005-04-11 2011-10-19 エフ.ホフマン−ラ ロシュ アーゲー (3,4−ジヒドロ−キナゾリン−2−イル)−インダン−1−イル−アミン
JP4796624B2 (ja) * 2005-05-04 2011-10-19 エフ.ホフマン−ラ ロシュ アーゲー 5−ht受容体に作用する(3,4−ジヒドロ−キナゾリン−2−イル)−(2−アリールオキシ−エチル)−アミン類
WO2007067489A1 (en) * 2005-12-05 2007-06-14 Merck & Co., Inc. Quinolone m1 receptor positive allosteric modulators
WO2007075901A2 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
AU2007225088B2 (en) * 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
EP1886996A1 (en) * 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
JP2010500330A (ja) * 2006-08-10 2010-01-07 フエルレル インターナショナル,ソシエダッド アノニマ Gabaa受容体に対して親和性を有する1h−キノリン−4−オン化合物、方法、使用及び組成物
SI2074123T1 (sl) 2006-10-16 2013-03-29 Bionomics Limited Nove anksiolitične spojine
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
WO2009040377A2 (en) * 2007-09-27 2009-04-02 Ge Healthcare Limited Imaging agents
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
JP2012506857A (ja) * 2008-10-23 2012-03-22 メルク・シャープ・エンド・ドーム・コーポレイション 縮合複素環式m1受容体ポジティブアロステリック調節因子
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
US20120093917A1 (en) * 2009-04-02 2012-04-19 Robert Hromas Metnase and intnase inhibitors and their use in treating cancer
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2680842A4 (en) * 2011-03-02 2014-10-29 Bionomics Ltd METHOD FOR THE TREATMENT OF A DISEASE OR A SENSE OF THE CENTRAL NERVOUS SYSTEM
WO2012116415A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
CN103649086A (zh) 2011-05-12 2014-03-19 生态学有限公司 制备萘啶的方法
EP2819670B1 (en) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical Composition and Their Administration
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN107501107A (zh) * 2017-09-26 2017-12-22 兰亚朝 喹诺酮药物的中间体合成方法
CN111269131B (zh) * 2020-03-12 2021-12-28 江苏飞宇医药科技股份有限公司 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
JPS5715760B2 (enExample) * 1974-06-11 1982-04-01
US4390541A (en) * 1980-12-19 1983-06-28 Lilly Industries Limited Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
MXPA01011173A (es) * 1999-05-06 2002-04-24 Neurogen Corp 4-0x0-quinolin-3-carboxamidas sustituidas: ligandos del receptor cerebro de gaba.
GB0127349D0 (en) * 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
EP1503759B1 (en) * 2002-05-14 2008-12-17 The Regents Of The University Of California Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

Also Published As

Publication number Publication date
EP1503759A4 (en) 2006-02-15
ES2319176T3 (es) 2009-05-05
AU2003229043B2 (en) 2008-12-04
JP4532263B2 (ja) 2010-08-25
MXPA04011156A (es) 2005-02-17
EP1503759A2 (en) 2005-02-09
NZ536061A (en) 2008-09-26
DK1503759T3 (da) 2009-04-14
IL164734A0 (en) 2005-12-18
WO2003097564A3 (en) 2004-02-26
JP2005535592A (ja) 2005-11-24
DE60325347D1 (de) 2009-01-29
CA2484308A1 (en) 2003-11-27
AU2003229043A1 (en) 2003-12-02
US20060178516A1 (en) 2006-08-10
US20080176897A1 (en) 2008-07-24
HK1072905A1 (en) 2005-09-16
CN1652784A (zh) 2005-08-10
WO2003097564A2 (en) 2003-11-27
US7355047B2 (en) 2008-04-08
ATE417613T1 (de) 2009-01-15
EP1503759B1 (en) 2008-12-17
KR20040107525A (ko) 2004-12-20

Similar Documents

Publication Publication Date Title
DK1503759T3 (da) Substituerede quinoloncarboxylsyrer, deres derivater, virkningssted og anvendelser heraf
US5091171B1 (en) Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
DK0562512T3 (da) Sulfonamidocarbonylpyridin-2-carboxylsyreamider samt deres anvendelse som lægemidler
BR9900766A (pt) Conexão em ação direta da articulação de barra estabilizadora.
IT1298214B1 (it) Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche.
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
BR0311437A (pt) Tts de fusão a quente para a administração de rotigotina
TR200201004T2 (tr) Monoamin reuptake önleyicileri olarak biaril eter türevleri
BR9205658A (pt) Marcador de pavimento, laminado adesivo sensivel á pressáo para fixar um marcador de pavimento para uma superficie de rodovia, marcador suspenso de pavimento, e, processo de marcaçao de um pavimento apresentando uma superficie de rodovia com uma temperatura abaixo de 15°c
DE60143393D1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
ATE517615T1 (de) Schmerzstillendes und entzündungshemmendes pflaster zur lokalen anwendung
PT933993E (pt) Compostos de ciclopentano substituidos, uteis como inibidores de neuraminidase
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
DK1439830T3 (da) Farmaceutisk præparat med 2-(4-isobutylphenyl)propionsyre
DE69626698D1 (de) Kugelförmige abdruckkappe
BRPI0510715A (pt) enaminonas substituìdas, seus derivados e usos destas
ES2126684T3 (es) Utilizacion de derivados de acidos carboxilicos aromaticos para la preparacion de medicamentos.
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales
ITTO920303A1 (it) Composizione farmaceutica antiinfiammatoria
DE60104662D1 (de) Eine Anti-Trauma Knochenplatte zum Fixieren von Kieferstümpfen
FI941911A0 (fi) Kondensoidut kinolyylidihydropyridiinit, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
HUP0203152A2 (hu) Eljárás és kompozíciók pulmonalis betegségek kezelésére
SE460333B (sv) Anordning foer uppbaerande av en tandprotes och foerfarande foer dess tillverkning
PT1051654E (pt) Conjunto para insercao de apoios de nariz com duplo objectivo
BR9713349A (pt) Método e dispositivo para adaptar uma estrutura de ponte para ajustar elementos de ancoragem em uma mandìbula de paciente.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/47; C07D 215/16, 215/20; A61P 25/00

Ipc: A61K 31/47 (2011.01), C07D 215/16 (2011.01), C07D

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 8A E 9A ANUIDADES.